PTX-35: A potential first-in-class T cell co-stimulator targeting TNFRSF25 (Death Receptor 3)
PTX-35 is a potential first-in-class T cell co-stimulator targeting TNFRSF25 (Death Receptor 3). Favorable safety profile was demonstrated in mice and non-human primates. PTX-35’s development plan focuses on cancer immunotherapy.
Pelican has been awarded a $15.2 million Cancer Prevention Institute of Texas (CPRIT) grant (the “CPRIT Grant”) to support development of PTX-35 and to fund a 70-patient Phase 1 clinical trial.
| Program | Mechanism of Action (Modality) |
Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|
PTX-35 |
TNFRSF25 (Antibody) |
SOLID TUMORS |
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|